Moderna
-
Could the Moderna-Merck Melanoma Vaccine Win FDA Approval Within Two Years? What We Know
Intismeran met primary endpoints in phase 3, but FDA filing date remains unannounced as companies race toward potential 2027 approval.
-
Moderna and Merck’s Personalized Melanoma Vaccine Cuts Recurrence Risk by 42% in Late-Stage Trial
By sequencing individual tumors to target unique neoantigens, Moderna’s platform creates bespoke vaccines in nine weeks, cutting melanoma recurrence risk by 42%.
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
The numbers first: 1,137 patients, split two to one, all with melanoma that surgeons had already removed. On Wednesday, 19 August 2026,…
-
Merck and Moderna Report Phase 3 Win for mRNA Melanoma Therapy Plus Keytruda
New York, August 20 — Merck and Moderna announced successful results from a late-stage clinical trial for an mRNA-based cancer vaccine targeting…
-
Moderna’s New mNEXSPIKE COVID-19 Vaccine Wins FDA Approval After Phase 3 Trial
The Moderna COVID-19 vaccine, also known as Spikevax, has been a crucial tool in the fight against COVID-19, a disease caused by…
-
Moderna’s KRAS Cancer Vaccine Candidate Was Dropped by Merck After Phase 1 Enrollment
In the realm of cancer research, the tetravalent vaccine candidate, code-named V941 or mRNA-5671, developed by Moderna, continues to garner attention within…
-
Moderna Ships New Vaccine to Test Third Dose Against B.1.351 Variant
On 26 February 2020, a modest consignment departed Moderna’s Cambridge, Massachusetts plant carrying vials of the experimental vaccine mRNA‑1273. The shipment’s destination…
-
Moderna Ships Experimental Coronavirus Vaccine for Clinical Testing Quickly
U.S. biotechnology company Moderna Inc. dispatched its first shipment of an experimental coronavirus vaccine, designated mRNA-1273, to the National Institute of Allergy…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992